Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 383

1.

Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines.

Michaelis M, Voges Y, Rothweiler F, Weipert F, Zia-Ahmad A, Cinatl J, von Deimling A, Westermann F, Rödel F, Wass MN, Cinatl J Jr.

Cancers (Basel). 2020 Mar 2;12(3). pii: E577. doi: 10.3390/cancers12030577.

2.

Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin.

Dilruba S, Grondana A, Schiedel AC, Ueno NT, Bartholomeusz C, Cinatl J Jr, McLaughlin KM, Wass MN, Michaelis M, Kalayda GV.

Cells. 2020 Feb 24;9(2). pii: E515. doi: 10.3390/cells9020515.

3.

Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China.

Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, Behrens P, Böddinghaus B, Götsch U, Naujoks F, Neumann P, Schork J, Tiarks-Jungk P, Walczok A, Eickmann M, Vehreschild MJGT, Kann G, Wolf T, Gottschalk R, Ciesek S.

N Engl J Med. 2020 Mar 26;382(13):1278-1280. doi: 10.1056/NEJMc2001899. Epub 2020 Feb 18. No abstract available.

PMID:
32069388
4.

Tumor necrosis factor‑related apoptosis‑inducing ligand as a therapeutic option in urothelial cancer cells with acquired resistance against first‑line chemotherapy.

Vallo S, Stege H, Berg M, Michaelis M, Winkelmann R, Rothweiler F, Cinatl J Jr.

Oncol Rep. 2020 Apr;43(4):1331-1337. doi: 10.3892/or.2020.7487. Epub 2020 Feb 3.

PMID:
32020226
5.

The Acinetobacter trimeric autotransporter adhesin Ata controls key virulence traits of Acinetobacter baumannii.

Weidensdorfer M, Ishikawa M, Hori K, Linke D, Djahanschiri B, Iruegas R, Ebersberger I, Riedel-Christ S, Enders G, Leukert L, Kraiczy P, Rothweiler F, Cinatl J, Berger J, Hipp K, Kempf VAJ, Göttig S.

Virulence. 2019 Dec;10(1):68-81. doi: 10.1080/21505594.2018.1558693.

6.

The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation.

Vogel JU, Schmidt S, Schmidt D, Rothweiler F, Koch B, Baer P, Rabenau H, Michel D, Stamminger T, Michaelis M, Cinatl J.

Cells. 2019 Dec 20;9(1). pii: E31. doi: 10.3390/cells9010031.

7.

Omeprazole Increases the Efficacy of Acyclovir Against Herpes Simplex Virus Type 1 and 2.

Michaelis M, Kleinschmidt MC, Bojkova D, Rabenau HF, Wass MN, Cinatl J Jr.

Front Microbiol. 2019 Dec 3;10:2790. doi: 10.3389/fmicb.2019.02790. eCollection 2019.

8.

Thiourea and Guanidine Compounds and Their Iridium Complexes in Drug-Resistant Cancer Cell Lines: Structure-Activity Relationships and Direct Luminescent Imaging.

Thomas SJ, Balónová B, Cinatl J Jr, Wass MN, Serpell CJ, Blight BA, Michaelis M.

ChemMedChem. 2020 Feb 17;15(4):349-353. doi: 10.1002/cmdc.201900591. Epub 2019 Dec 20.

PMID:
31828886
9.

Incorporation of doxorubicin in different polymer nanoparticles and their anticancer activity.

Pieper S, Onafuye H, Mulac D, Cinatl J Jr, Wass MN, Michaelis M, Langer K.

Beilstein J Nanotechnol. 2019 Oct 29;10:2062-2072. doi: 10.3762/bjnano.10.201. eCollection 2019.

10.

Isolation, Characterization, Differentiation and Immunomodulatory Capacity of Mesenchymal Stromal/Stem Cells from Human Perirenal Adipose Tissue.

Baer PC, Koch B, Hickmann E, Schubert R, Cinatl J Jr, Hauser IA, Geiger H.

Cells. 2019 Oct 29;8(11). pii: E1346. doi: 10.3390/cells8111346.

11.

Intact-Cell MALDI-ToF Mass Spectrometry for the Authentication of Drug-Adapted Cancer Cell Lines.

Povey JF, Saintas E, Aderemi AV, Rothweiler F, Zehner R, Dirks WG, Cinatl J Jr, Racher AJ, Wass MN, Smales CM, Michaelis M.

Cells. 2019 Oct 2;8(10). pii: E1194. doi: 10.3390/cells8101194.

12.

Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells.

Onafuye H, Pieper S, Mulac D, Cinatl J Jr, Wass MN, Langer K, Michaelis M.

Beilstein J Nanotechnol. 2019 Aug 14;10:1707-1715. doi: 10.3762/bjnano.10.166. eCollection 2019.

13.

Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.

Oellerich T, Schneider C, Thomas D, Knecht KM, Buzovetsky O, Kaderali L, Schliemann C, Bohnenberger H, Angenendt L, Hartmann W, Wardelmann E, Rothenburger T, Mohr S, Scheich S, Comoglio F, Wilke A, Ströbel P, Serve H, Michaelis M, Ferreirós N, Geisslinger G, Xiong Y, Keppler OT, Cinatl J Jr.

Nat Commun. 2019 Aug 2;10(1):3475. doi: 10.1038/s41467-019-11413-4.

14.

The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1.

Knecht KM, Buzovetsky O, Schneider C, Thomas D, Srikanth V, Kaderali L, Tofoleanu F, Reiss K, Ferreirós N, Geisslinger G, Batista VS, Ji X, Cinatl J Jr, Keppler OT, Xiong Y.

Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10022-E10031. doi: 10.1073/pnas.1805593115. Epub 2018 Oct 10.

15.

Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus.

Cocking D, Cinatl J, Boltz DA, Peng X, Johnson W, Muzzio M, Syarkevych O, Kostyuk G, Goy A, Mueller L, Margitich VI.

Acta Virol. 2018;62(2):191-195. doi: 10.4149/av_2018_211.

PMID:
29895160
16.

Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer.

Jenks AD, Vyse S, Wong JP, Kostaras E, Keller D, Burgoyne T, Shoemark A, Tsalikis A, de la Roche M, Michaelis M, Cinatl J Jr, Huang PH, Tanos BE.

Cell Rep. 2018 Jun 5;23(10):3042-3055. doi: 10.1016/j.celrep.2018.05.016.

17.

Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach.

Sarin N, Engel F, Rothweiler F, Cinatl J, Michaelis M, Frötschl R, Fröhlich H, Kalayda GV.

Int J Mol Sci. 2018 Mar 7;19(3). pii: E767. doi: 10.3390/ijms19030767.

18.

BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells.

Das CK, Linder B, Bonn F, Rothweiler F, Dikic I, Michaelis M, Cinatl J, Mandal M, Kögel D.

Neoplasia. 2018 Mar;20(3):263-279. doi: 10.1016/j.neo.2018.01.001. Epub 2018 Feb 22.

19.

A cell culture platform for Cryptosporidium that enables long-term cultivation and new tools for the systematic investigation of its biology.

Miller CN, Jossé L, Brown I, Blakeman B, Povey J, Yiangou L, Price M, Cinatl J Jr, Xue WF, Michaelis M, Tsaousis AD.

Int J Parasitol. 2018 Mar;48(3-4):197-201. doi: 10.1016/j.ijpara.2017.10.001. Epub 2017 Nov 28.

20.

Blocking integrin β1 decreases adhesion in chemoresistant urothelial cancer cell lines.

Vallo S, Rutz J, Kautsch M, Winkelmann R, Michaelis M, Wezel F, Bartsch G, Haferkamp A, Rothweiler F, Blaheta RA, Cinatl J Jr.

Oncol Lett. 2017 Nov;14(5):5513-5518. doi: 10.3892/ol.2017.6883. Epub 2017 Sep 4.

21.

Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.

Sarin N, Engel F, Kalayda GV, Mannewitz M, Cinatl J Jr, Rothweiler F, Michaelis M, Saafan H, Ritter CA, Jaehde U, Frötschl R.

PLoS One. 2017 Jul 26;12(7):e0181081. doi: 10.1371/journal.pone.0181081. eCollection 2017.

22.

The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis.

Kollareddy M, Sherrard A, Park JH, Szemes M, Gallacher K, Melegh Z, Oltean S, Michaelis M, Cinatl J Jr, Kaidi A, Malik K.

Cancer Lett. 2017 Sep 10;403:74-85. doi: 10.1016/j.canlet.2017.05.027. Epub 2017 Jun 7.

23.

Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells.

Vallo S, Köpp R, Michaelis M, Rothweiler F, Bartsch G, Brandt MP, Gust KM, Wezel F, Blaheta RA, Haferkamp A, Cinatl J Jr.

Oncol Lett. 2017 Jun;13(6):4085-4092. doi: 10.3892/ol.2017.5986. Epub 2017 Apr 5.

24.

Corrigendum: SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.

Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E, Comoglio F, Hansmann ML, Yakunin AF, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler OT, Cinatl J Jr.

Nat Med. 2017 Jun 6;23(6):788. doi: 10.1038/nm0617-788a. No abstract available.

PMID:
28586337
25.

Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS.

Saintas E, Abrahams L, Ahmad GT, Ajakaiye AM, AlHumaidi AS, Ashmore-Harris C, Clark I, Dura UK, Fixmer CN, Ike-Morris C, Mato Prado M, Mccullough D, Mishra S, Schöler KM, Timur H, Williamson MD, Alatsatianos M, Bahsoun B, Blackburn E, Hogwood CE, Lithgow PE, Rowe M, Yiangou L, Rothweiler F, Cinatl J Jr, Zehner R, Baines AJ, Garrett MD, Gourlay CW, Griffin DK, Gullick WJ, Hargreaves E, Howard MJ, Lloyd DR, Rossman JS, Smales CM, Tsaousis AD, von der Haar T, Wass MN, Michaelis M.

PLoS One. 2017 Feb 13;12(2):e0172140. doi: 10.1371/journal.pone.0172140. eCollection 2017.

26.

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.

Isono M, Hoffmann MJ, Pinkerneil M, Sato A, Michaelis M, Cinatl J Jr, Niegisch G, Schulz WA.

J Exp Clin Cancer Res. 2017 Jan 3;36(1):1. doi: 10.1186/s13046-016-0473-1.

27.

SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.

Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E, Comoglio F, Hansmann ML, Yakunin AF, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler OT, Cinatl J Jr.

Nat Med. 2017 Feb;23(2):250-255. doi: 10.1038/nm.4255. Epub 2016 Dec 19. Erratum in: Nat Med. 2017 Jun 6;23 (6):788.

PMID:
27991919
28.

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.

Voges Y, Michaelis M, Rothweiler F, Schaller T, Schneider C, Politt K, Mernberger M, Nist A, Stiewe T, Wass MN, Rödel F, Cinatl J.

Cell Death Dis. 2016 Oct 13;7(10):e2410. doi: 10.1038/cddis.2016.257.

29.

Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts.

Vallo S, Michaelis M, Gust KM, Black PC, Rothweiler F, Kvasnicka HM, Blaheta RA, Brandt MP, Wezel F, Haferkamp A, Cinatl J Jr.

BMC Res Notes. 2016 Sep 27;9(1):454.

30.

Knowledge-based approach to identify key determinants of cisplatin sensitivity
.

Sarin N, Engel F, Kalayda GV, Frötschl R, Cinatl J Jr, Rothweiler F, Michaelis M, Fröhlich H, Jaehde U.

Int J Clin Pharmacol Ther. 2017 Aug;55(8):686-689. doi: 10.5414/CPXCES15EA04. No abstract available.

PMID:
27641214
31.

ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance.

Löschmann N, Michaelis M, Rothweiler F, Voges Y, Balónová B, Blight BA, Cinatl J Jr.

Oncotarget. 2016 Sep 6;7(36):58051-58064. doi: 10.18632/oncotarget.11160.

32.

Utilising the EGFR interactome to identify mechanisms of drug resistance in non-small cell lung cancer - Proof of concept towards a systems pharmacology approach.

Saafan H, Foerster S, Parra-Guillen ZP, Hammer E, Michaelis M, Cinatl J Jr, Völker U, Fröhlich H, Kloft C, Ritter CA.

Eur J Pharm Sci. 2016 Oct 30;94:20-32. doi: 10.1016/j.ejps.2016.04.025. Epub 2016 Apr 23.

PMID:
27112992
33.

Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport.

Michaelis M, Rothweiler F, Wurglics M, Aniceto N, Dittrich M, Zettl H, Wiese M, Wass M, Ghafourian T, Schubert-Zsilavecz M, Cinatl J.

Oncotarget. 2016 Mar 8;7(10):11664-76. doi: 10.18632/oncotarget.7345.

34.

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib.

Michaelis M, Selt F, Rothweiler F, Wiese M, Cinatl J Jr.

BMC Res Notes. 2015 Sep 28;8:484. doi: 10.1186/s13104-015-1405-4.

35.

Relevance of subcellular localization of extracellular signal-regulated kinase 1/2 (ERK1/2) for cisplatin resistance.

Dilruba S, Michaelis M, Cinatl J Jr, Kalayda GV.

Int J Clin Pharmacol Ther. 2015 Dec;53(12):1041-5. doi: 10.5414/CPXCES14EA03. No abstract available.

PMID:
26249763
36.

Towards an unbiased, collaborative effort to reach evidence about the presence of human cytomegalovirus in glioblastoma (and other tumors).

Michaelis M, Mittelbronn M, Cinatl J Jr.

Neuro Oncol. 2015 Jul;17(7):1039. doi: 10.1093/neuonc/nov048. No abstract available.

37.

Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.

Pfirrmann V, Oelsner S, Rettinger E, Huenecke S, Bonig H, Merker M, Wels WS, Cinatl J, Schubert R, Klingebiel T, Bader P.

Cytotherapy. 2015 Aug;17(8):1139-51. doi: 10.1016/j.jcyt.2015.04.011. Epub 2015 Jun 10.

PMID:
26072027
38.

Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics.

Vallo S, Michaelis M, Rothweiler F, Bartsch G, Gust KM, Limbart DM, Rödel F, Wezel F, Haferkamp A, Cinatl J Jr.

Transl Oncol. 2015 Jun;8(3):210-6. doi: 10.1016/j.tranon.2015.04.002.

39.

Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (-)-Gossypol (AT-101).

Mani J, Vallo S, Rakel S, Antonietti P, Gessler F, Blaheta R, Bartsch G, Michaelis M, Cinatl J, Haferkamp A, Kögel D.

BMC Cancer. 2015 Apr 7;15:224. doi: 10.1186/s12885-015-1239-4.

40.

Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status.

Michaelis M, Rothweiler F, Löschmann N, Sharifi M, Ghafourian T, Cinatl J Jr.

Oncotarget. 2015 Jul 10;6(19):17605-20.

41.

Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.

Michaelis M, Agha B, Rothweiler F, Löschmann N, Voges Y, Mittelbronn M, Starzetz T, Harter PN, Abhari BA, Fulda S, Westermann F, Riecken K, Spek S, Langer K, Wiese M, Dirks WG, Zehner R, Cinatl J, Wass MN, Cinatl J Jr.

Sci Rep. 2015 Feb 3;5:8202. doi: 10.1038/srep08202.

42.

Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression.

Michaelis M, Rothweiler F, Nerreter T, van Rikxoort M, Zehner R, Dirks WG, Wiese M, Cinatl J Jr.

BMC Res Notes. 2014 Oct 10;7:710. doi: 10.1186/1756-0500-7-710.

43.

Aurora kinases as targets in drug-resistant neuroblastoma cells.

Michaelis M, Selt F, Rothweiler F, Löschmann N, Nüsse B, Dirks WG, Zehner R, Cinatl J Jr.

PLoS One. 2014 Sep 30;9(9):e108758. doi: 10.1371/journal.pone.0108758. eCollection 2014.

44.

Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics.

Baumgarten P, Michaelis M, Rothweiler F, Starzetz T, Rabenau HF, Berger A, Jennewein L, Braczynski AK, Franz K, Seifert V, Steinbach JP, Allwinn R, Mittelbronn M, Cinatl J Jr.

Neuro Oncol. 2014 Nov;16(11):1469-77. doi: 10.1093/neuonc/nou167. Epub 2014 Aug 25.

45.

Resistance acquisition to MDM2 inhibitors.

Cinatl J, Speidel D, Hardcastle I, Michaelis M.

Biochem Soc Trans. 2014 Aug;42(4):752-7. doi: 10.1042/BST20140035. Review.

PMID:
25109953
46.

Effects of flavonoid-induced oxidative stress on anti-H5N1 influenza a virus activity exerted by baicalein and biochanin A.

Michaelis M, Sithisarn P, Cinatl J Jr.

BMC Res Notes. 2014 Jun 23;7:384. doi: 10.1186/1756-0500-7-384.

47.

Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 function.

Michaelis M, Rothweiler F, Nerreter T, Van Rikxoort M, Sharifi M, Wiese M, Ghafourian T, Cinatl J.

J Pharm Pharm Sci. 2014;17(1):154-68.

48.

Karanjin interferes with ABCB1, ABCC1, and ABCG2.

Michaelis M, Rothweiler F, Nerreter T, Sharifi M, Ghafourian T, Cinatl J.

J Pharm Pharm Sci. 2014;17(1):92-105.

49.

A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, Survivin, HIF and STAT3.

Stoleriu MG, Steger V, Mustafi M, Michaelis M, Cinatl J, Schneider W, Nolte A, Kurz J, Wendel HP, Schlensak C, Walker T.

Eur J Cardiothorac Surg. 2014 Nov;46(5):877-86. doi: 10.1093/ejcts/ezu087. Epub 2014 Mar 13.

PMID:
24627437
50.

Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs.

Löschmann N, Michaelis M, Rothweiler F, Zehner R, Cinatl J, Voges Y, Sharifi M, Riecken K, Meyer J, von Deimling A, Fichtner I, Ghafourian T, Westermann F, Cinatl J Jr.

Transl Oncol. 2013 Dec 1;6(6):685-96. eCollection 2013 Dec 1.

Supplemental Content

Loading ...
Support Center